Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1553641
PUBLISHER: Grand View Research | PRODUCT CODE: 1553641
Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Pediatric Vaccines Market Growth & Trends:
The global pediatric vaccines market size is expected to reach USD 49.46 billion by 2030, registering a CAGR of 4.1%, according to a new report by Grand View Research, Inc. Advancements in development of vaccines and new product launches are some of the major drivers of the market.
Increase in investments by companies to capture a larger market share is anticipated to propel growth. Some of the factors attributed to increase in investment are high growth prospects in the emerging market, immunization schedule mandated by doctors for children, and awareness programs led by UNICEF, WHO, and other healthcare organizations. Furthermore, increase in number of government initiatives for raising awareness about immunization is expected to boost the market for pediatric vaccines.
Advancements in development of novel adjuvants and therapeutic vaccines are expected to drive growth during the forecast period. Ongoing research in novel molecules targeted at specific mechanisms of action in the body is aimed at providing immunity against fatal diseases such as cancer and Zika virus disease. For instance, in June 2016, Inovio Pharmaceuticals, Inc. announced the initiation of phase I clinical trial for their Zika DNA vaccine named GLS-5700.
Pediatric Vaccines Market Report Highlights:
- By type, monovalent emerged as the largest segment due to factors such as high usage and increase in initiatives for R&D activities supported by various governments.
- Conjugate vaccines formed the dominant technology segment in terms of revenue in 2023. Higher adoption of these vaccines and increase in prevalence of infectious diseases contribute to its lead in the market for pediatric vaccines.
- By application, the measles, mumps, and rubella (MMR) segment is projected to grow at the fastest CAGR of 6.1% over the forecast period. This is attributable to the fact that there are still cases of measles, mumps, and rubella which are characteristics of children who have not been vaccinated in areas with poor coverage.
- North America held the largest revenue share in 2023. Its dominance in the market for pediatric vaccines is owing to factors such as local presence of major players in the industry and extensive R&D activities.
- The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increase in prevalence of infectious diseases and a large target population.
Product Code: GVR-2-68038-279-2
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Pediatric Vaccines Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Pediatric Vaccines Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Pediatric Vaccines Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Pediatric Vaccines Market: Type Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Monovalent
- 4.3.1. Monovalent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Multivalent
- 4.4.1. Multivalent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Pediatric Vaccines Market: Technology Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Pediatric Vaccines Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
- 5.3. Live Attenuated Vaccines
- 5.3.1. Live Attenuated Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Inactivated Vaccines
- 5.4.1. Inactivated Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Subunit Vaccines
- 5.5.1. Subunit Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Toxoid Vaccines
- 5.6.1. Toxoid Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Conjugate Vaccines
- 5.7.1. Conjugate Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8. Others
- 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Pediatric Vaccines Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Pediatric Vaccines Market: Application Movement Analysis, 2023 & 2030 (USD Million)
- 6.3. Infectious Disease
- 6.3.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Cancer
- 6.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Allergy
- 6.5.1. Allergy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Pneumococcal Diseases
- 6.6.1. Pneumococcal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. Influenza
- 6.7.1. Influenza Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.8. Measles, Mumps, and Rubella (MMR)
- 6.8.1. Measles, Mumps, and Rubella (MMR) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.9. Other Application
- 6.9.1. Other Application Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Pediatric Vaccines Market: Regional Estimates & Trend Analysis
- 7.1. Pediatric Vaccines Market Share, By Region, 2023 & 2030 (USD Million)
- 7.2. North America
- 7.2.1. North America Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Canada Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Mexico Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
- 7.3.2.1. UK Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Germany Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. France Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Italy Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Spain Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Denmark Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Sweden Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Norway Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
- 7.4.2.1. China Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
- 7.4.3.1. Japan Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. India Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. South Korea Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Australia Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Thailand Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Brazil Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Argentina Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
- 7.6.2.1. Saudi Arabia Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
- 7.6.3.1. UAE Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
- 7.6.4.1. South Africa Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Kuwait Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. AstraZeneca
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Sanofi
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. GSK plc
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Pfizer, Inc.
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Zydus Group
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Indian Immunologicals Ltd.
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Serum Institute of India Pvt. Ltd.
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Panacea Biotec
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. SINOVAC
- 8.4.9.1. Participant's Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. BIO-MED
- 8.4.10.1. Participant's Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.1. AstraZeneca
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.